Sivec Biotechnologies
SiVEC Biotechnologies is a pioneering biotech company focused on developing advanced biologics and innovative drug delivery platforms, notably the BactPac™ live biotherapeutic delivery system. Their mission is to enable the next generation of nucleic acid and gene editing therapies through safe, targeted, and efficient delivery solutions, aiming to revolutionize treatment outcomes and address major challenges in oncology, gene therapy, and infectious diseases.
Industries
Nr. of Employees
small (1-50)
Patents
Products
Bacterial-delivered intracellular anti-KRAS single-domain antibody therapy (preclinical)
A preclinical therapeutic approach where engineered bacterial vehicles express and deliver a single-domain antibody intracellularly to inhibit oncogenic KRAS signaling in tumors; demonstrated tumor volume reductions in xenograft mouse models.
Bacterial-delivered survivin-targeting oncology therapeutic (preclinical)
A cancer therapeutic designed to inhibit the anti-apoptotic protein survivin, intended for use alone or combined with chemotherapy to enhance efficacy and reduce side effects.
Inhaled bacterial-delivered siRNA antiviral for influenza (IND-enabling)
An inhalable live bacterial-delivered siRNA therapeutic targeting conserved influenza gene regions for rapid, broad protection against type A influenza; reported to be in IND-enabling studies.
Bacterial-delivered intracellular anti-KRAS single-domain antibody therapy (preclinical)
A preclinical therapeutic approach where engineered bacterial vehicles express and deliver a single-domain antibody intracellularly to inhibit oncogenic KRAS signaling in tumors; demonstrated tumor volume reductions in xenograft mouse models.
Bacterial-delivered survivin-targeting oncology therapeutic (preclinical)
A cancer therapeutic designed to inhibit the anti-apoptotic protein survivin, intended for use alone or combined with chemotherapy to enhance efficacy and reduce side effects.
Inhaled bacterial-delivered siRNA antiviral for influenza (IND-enabling)
An inhalable live bacterial-delivered siRNA therapeutic targeting conserved influenza gene regions for rapid, broad protection against type A influenza; reported to be in IND-enabling studies.
Services
Out-licensing or collaborative access to a bacteria-based delivery platform for development of therapeutics across indications.
Support for preclinical efficacy testing and IND-enabling studies for delivery-enabled therapeutics.
Partnership formation with industry partners to adapt the delivery platform to partner cargo and indications.
Out-licensing or collaborative access to a bacteria-based delivery platform for development of therapeutics across indications.
Support for preclinical efficacy testing and IND-enabling studies for delivery-enabled therapeutics.
Partnership formation with industry partners to adapt the delivery platform to partner cargo and indications.
Expertise Areas
- Microbial vector engineering
- Nucleic acid therapeutic delivery
- Intracellular protein delivery
- Gene-editing delivery (RNP)
Key Technologies
- Live bacterial delivery vectors
- shRNA / siRNA delivery
- Linear and circular translatable mRNA expression
- CRISPR/Cas ribonucleoprotein delivery
News & Updates
SiVEC Biotechnologies is featured in Nature’s Biopharma Dealmakers, highlighting how their BactPac™ platform is reshaping gene and RNA therapy delivery.
SiVEC Biotechnologies won in the 2024 BioChallenge pitch competition, securing a share of $100,000 for their BactPac platform.
SiVEC announced significant preclinical efficacy data for SVC-KRAb, a therapy targeting KRAS mutations in cancer.
SiVEC secured victory in the NIH TARGETED Challenge, advancing genome editing delivery technology.
Lyndsey Linke, CEO of SiVEC, discussed her journey and the company's innovations in biotech.
Lyndsey Linke, CEO of SiVEC, was appointed as a new board member for CBSA.
SiVEC Biotechnologies is featured in Nature’s Biopharma Dealmakers, highlighting how their BactPac™ platform is reshaping gene and RNA therapy delivery.
SiVEC Biotechnologies won in the 2024 BioChallenge pitch competition, securing a share of $100,000 for their BactPac platform.
SiVEC announced significant preclinical efficacy data for SVC-KRAb, a therapy targeting KRAS mutations in cancer.
SiVEC secured victory in the NIH TARGETED Challenge, advancing genome editing delivery technology.
Lyndsey Linke, CEO of SiVEC, discussed her journey and the company's innovations in biotech.
Lyndsey Linke, CEO of SiVEC, was appointed as a new board member for CBSA.